120 related articles for article (PubMed ID: 38565301)
1. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib.
Zhang Y; Feng J; Mi Y; Fan W; Qin R; Mei Y; Jin G; Mao J; Zhang H
Drug Metab Dispos; 2024 May; 52(6):555-564. PubMed ID: 38565301
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
Ye CG; Chen GG; Ho RLK; Merchant JL; He ML; Lai PBS
Biochim Biophys Acta; 2013 Dec; 1833(12):2970-2979. PubMed ID: 23954442
[TBL] [Abstract][Full Text] [Related]
5. Aberrant CpG island hypermethylation and down-regulation of Oct-6 mRNA expression in human hepatocellular carcinoma.
Sun JZ; Yang XX; Li XH; Xu WW; Wang Y; Zhu W; Li M
Dig Dis Sci; 2011 Oct; 56(10):3072-7. PubMed ID: 21448695
[TBL] [Abstract][Full Text] [Related]
6. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative Effects of Epigenetic Modifier Drugs Through E-cadherin Up-regulation in Liver Cancer Cell Lines.
Uribe D; Cardona A; Esposti DD; Cros MP; Cuenin C; Herceg Z; Camargo M; Cortés-Mancera FM
Ann Hepatol; 2018; 17(3):444-460. PubMed ID: 29735783
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.
Ren J; Chen GG; Liu Y; Su X; Hu B; Leung BC; Wang Y; Ho RL; Yang S; Lu G; Lee CG; Lai PB
PLoS One; 2016; 11(4):e0153863. PubMed ID: 27093553
[TBL] [Abstract][Full Text] [Related]
9. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
Jung N; Won JK; Kim BH; Suh KS; Jang JJ; Kang GH
J Korean Med Sci; 2012 Jun; 27(6):594-604. PubMed ID: 22690089
[TBL] [Abstract][Full Text] [Related]
11. Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell.
Zhao Z; Wu Q; Cheng J; Qiu X; Zhang J; Fan H
J Biomed Biotechnol; 2010; 2010():737535. PubMed ID: 20467490
[TBL] [Abstract][Full Text] [Related]
12. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract][Full Text] [Related]
13. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
14. SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma.
Shikauchi Y; Saiura A; Kubo T; Niwa Y; Yamamoto J; Murase Y; Yoshikawa H
Mol Cell Biol; 2009 Apr; 29(7):1944-58. PubMed ID: 19139273
[TBL] [Abstract][Full Text] [Related]
15. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
17. miR-639 Expression Is Silenced by DNMT3A-Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer Cells.
Xiao J; Liu Y; Wu F; Liu R; Xie Y; Yang Q; Li Y; Liu M; Li S; Tang H
Mol Ther; 2020 Feb; 28(2):587-598. PubMed ID: 31843451
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.
Quan H; Zhou F; Nie D; Chen Q; Cai X; Shan X; Zhou Z; Chen K; Huang A; Li S; Tang N
Oncogene; 2014 May; 33(22):2826-35. PubMed ID: 23770846
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic and biological significance of DNA methyltransferase 1 upregulated by growth factors in human hepatocellular carcinoma.
Fang QL; Yin YR; Xie CR; Zhang S; Zhao WX; Pan C; Wang XM; Yin ZY
Int J Oncol; 2015 Feb; 46(2):782-90. PubMed ID: 25420499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
